Actelion Pharmaceuticals Ltd. has identified pyrazolopyrrolopyridazines acting as platelet-derived growth factor receptor β (PDGFR-β, PDGFRB) inhibitors reported to be useful for the treatment of pulmonary arterial hypertension.
A preclinical trial in mice and ferrets of an experimental mRNA vaccine against the H5 highly pathogenic avian influenza (HPAI) virus generated neutralizing antibodies and prevented severe illness and mortality of the animals.
Excessive inflammatory response and endothelial barrier dysfunction are the two major pathophysiological changes in acute respiratory distress syndrome (ARDS). Sphingosine-1-phosphate S1P3 receptor (S1PR3) is a G protein-coupled receptor involved in the regulation of inflammation and vascular barrier function in some diseases, but its function in ARDS is not fully understood.
Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.
Researchers from Federation University Australia and affiliated organizations have reported data from a study that aimed to assess the therapeutic efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in a large animal model of pulmonary fibrosis.
Alternative splicing is known to play an important role in tissue development. Scientists at Brigham and Women’s Hospital have looked into the association between a chronic obstructive pulmonary disease (COPD) genetic variant and cell-specific splicing of putative ciliary rootlet coiled-coil protein-like 1 protein (CROCCP2).
Acute respiratory distress syndrome (ARDS) is a multifactorial disease, the pathogenesis of which involves environmental exposure and genetic predisposition.
Mast/stem cell growth factor receptor KIT is a receptor tyrosine kinase that plays a key role in mast cell differentiation, proliferation, survival and activation.
The cannabinoid CB1 receptor inverse agonist INV-202 (monlunabant) is in clinical studies at Inversago Pharma Inc. as a potentially first-in-class drug for metabolic disorders, including diabetic kidney disease and obesity.